Found this study on the NIH website: "The present molecular docking and MD simulation studies suggest that the drug hydroxychloroquine may have considerable effect on structure protease of SARS-COV-2, which may lead to significant inhibitory effect on the latter."
But since no RCTs were ever performed using hydroxychloroquine/zinc/azithromycin on vulnerable, non-hospitalized patients, we had to "invent" a new drug.
Link: Hydroxychloroquine study on NIH website
This message has been edited 1 time(s).